Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00698243 · ClinicalTrials.gov registry record · Phase 1
Study of Oral OSI-027 in Patients With Advanced Solid Tumors or Lymphoma
A Phase 1 study, sponsored by Astellas Pharma.
- Completed
- Registry status
- Phase 1
- Development phase
- 128
- Enrollment target
NCT00698243 is a Phase 1 study that has completed, run by Astellas Pharma. The registered enrollment target is 128 participants.
The verdict
NCT00698243, a Phase 1 study, has completed, sponsored by Astellas Pharma.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 128 participants
- Enrollment target
Study Summary
The primary objective of this study is to determine the maximum tolerated dose (MTD) and to establish the recommended phase 2 dose of oral OSI-027 when administered via 3 schedules, namely, intermittent, weekly, and continuous in patients with advanced solid tumors or lymphoma, namely, intermittent, weekly, and continuous.
Interventions
- DRUG OSI-027
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 128 participants |
| Start Date | 2008-06 |
| Est. Completion | 2013-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00698243
The ClinicalTrials.gov registry entry for NCT00698243 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 128 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Astellas Pharma, which has 165 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which OSI-027 is the first listed.
NCT00698243 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00698243 about?
NCT00698243 is a clinical study titled "Study of Oral OSI-027 in Patients With Advanced Solid Tumors or Lymphoma". The primary objective of this study is to determine the maximum tolerated dose (MTD) and to establish the recommended phase 2 dose of oral OSI-027 when administered via 3 schedules, namely, intermittent, weekly, and continuous in patients with advanced solid tumors or lymphoma, namely, intermittent,...
What is the current status of trial NCT00698243?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 128 participants. The study started on 2008-06. Estimated completion is 2013-02.
What interventions are being tested in trial NCT00698243?
The interventions under investigation include: OSI-027 (DRUG).
Who is sponsoring clinical trial NCT00698243?
This trial is sponsored by Astellas Pharma, which has 165 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.